Additionally, altered expression of urothelial differentiation factors such as FOXA1 and loss of function mutations in chromatin remodeler proteins such as ARID1A are important in disease progression and contribute to tumor heterogeneity in BC. This evidence concerns the gene FOXA1 and breast cancer.